Probiotic Lactobacillus strains protect against myelosuppression and immunosuppression in cyclophosphamide-treated mice

Autores
Salva, Maria Susana; Marranzino, Gabriela; Villena, Julio Cesar; Agüero, Graciela; Alvarez, Gladis Susana
Año de publicación
2014
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
This work evaluated the capacity of two probiotic strains, Lactobacillus casei CRL431 and Lactobacillus rhamnosus CRL1506, to protect against myelosuppression and immunosuppression in cyclophosphamide (Cy)-treated mice. Changes inmature granulocytes and progenitor cells in bonemarrow (BM) and blood were studied. In addition, the ability of probiotics to accelerate the recovery of the immune response against the opportunistic pathogen Candida albicans was evaluated.We demonstrated for the first time that the preventive treatmentwith immunomodulatory lactobacilli such as L. casei CRL431 or L. rhamnosus CRL1506 was able to increase immature myeloid progenitors in the BM, allowing an early recovery of myeloid cells after Cy administration. Probiotic lactobacilli were also capable to induce an early recovery of neutrophils in blood, improve phagocytic cells recruitment to infectious sites and increase the resistance against the opportunistic pathogen C. albicans. Although deeper studies regarding the cellular and molecularmechanisms of probiotic actions are needed, these findings support the idea that strains like CRL431 and CRL1506 may accelerate the recovery of Cy-caused immunosuppression by immunopotentiating myeloid cells. Then, probiotic lactobacilli have the potential to be used as alternatives for lessening chemotherapy-induced immunosuppression in cancer patients.
Fil: Salva, Maria Susana. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Tucumán. Centro de Referencia para Lactobacilos (i); Argentina
Fil: Marranzino, Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Tucumán. Centro de Referencia para Lactobacilos (i); Argentina
Fil: Villena, Julio Cesar. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Tucumán. Centro de Referencia para Lactobacilos (i); Argentina
Fil: Agüero, Graciela. Universidad Nacional de Tucuman. Facultad de Bioquimica, Quimica y Farmacia. Instituto de Bioquimica Clinica Aplicada. Catedra de Bioquimica Clinica I; Argentina
Fil: Alvarez, Gladis Susana. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Tucumán. Centro de Referencia para Lactobacilos (i); Argentina. Universidad Nacional de Tucuman. Facultad de Bioquimica, Quimica y Farmacia. Instituto de Bioquimica Clinica Aplicada. Catedra de Bioquimica Clinica I; Argentina
Materia
CYCLOPHOSPHAMIDE
IMMUNOBIOTICS
IMMUNOSUPPRESSION
LACTOBACILLUS CASEI CRL431
LACTOBACILLUS RHAMNOSUS CRL1506
MYELOPOIESIS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/2839
Acceder
id CONICETDig_b9815dfc7a509b1468af694bfee01214
oai_identifier_str oai:ri.conicet.gov.ar:11336/2839
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Probiotic Lactobacillus strains protect against myelosuppression and immunosuppression in cyclophosphamide-treated miceSalva, Maria SusanaMarranzino, GabrielaVillena, Julio CesarAgüero, GracielaAlvarez, Gladis SusanaCYCLOPHOSPHAMIDEIMMUNOBIOTICSIMMUNOSUPPRESSIONLACTOBACILLUS CASEI CRL431LACTOBACILLUS RHAMNOSUS CRL1506MYELOPOIESIShttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3This work evaluated the capacity of two probiotic strains, Lactobacillus casei CRL431 and Lactobacillus rhamnosus CRL1506, to protect against myelosuppression and immunosuppression in cyclophosphamide (Cy)-treated mice. Changes inmature granulocytes and progenitor cells in bonemarrow (BM) and blood were studied. In addition, the ability of probiotics to accelerate the recovery of the immune response against the opportunistic pathogen Candida albicans was evaluated.We demonstrated for the first time that the preventive treatmentwith immunomodulatory lactobacilli such as L. casei CRL431 or L. rhamnosus CRL1506 was able to increase immature myeloid progenitors in the BM, allowing an early recovery of myeloid cells after Cy administration. Probiotic lactobacilli were also capable to induce an early recovery of neutrophils in blood, improve phagocytic cells recruitment to infectious sites and increase the resistance against the opportunistic pathogen C. albicans. Although deeper studies regarding the cellular and molecularmechanisms of probiotic actions are needed, these findings support the idea that strains like CRL431 and CRL1506 may accelerate the recovery of Cy-caused immunosuppression by immunopotentiating myeloid cells. Then, probiotic lactobacilli have the potential to be used as alternatives for lessening chemotherapy-induced immunosuppression in cancer patients.Fil: Salva, Maria Susana. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Tucumán. Centro de Referencia para Lactobacilos (i); ArgentinaFil: Marranzino, Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Tucumán. Centro de Referencia para Lactobacilos (i); ArgentinaFil: Villena, Julio Cesar. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Tucumán. Centro de Referencia para Lactobacilos (i); ArgentinaFil: Agüero, Graciela. Universidad Nacional de Tucuman. Facultad de Bioquimica, Quimica y Farmacia. Instituto de Bioquimica Clinica Aplicada. Catedra de Bioquimica Clinica I; ArgentinaFil: Alvarez, Gladis Susana. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Tucumán. Centro de Referencia para Lactobacilos (i); Argentina. Universidad Nacional de Tucuman. Facultad de Bioquimica, Quimica y Farmacia. Instituto de Bioquimica Clinica Aplicada. Catedra de Bioquimica Clinica I; ArgentinaElsevier Science2014-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/2839Salva, Maria Susana; Marranzino, Gabriela; Villena, Julio Cesar; Agüero, Graciela; Alvarez, Gladis Susana; Probiotic Lactobacillus strains protect against myelosuppression and immunosuppression in cyclophosphamide-treated mice; Elsevier Science; International Immunopharmacology; 22; 1; 9-2014; 209-2211567-5769enginfo:eu-repo/semantics/altIdentifier/url/http://sciencedirect.com/science/journal/15675769info:eu-repo/semantics/altIdentifier/doi/10.1016/j.intimp.2014.06.017info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:53:01Zoai:ri.conicet.gov.ar:11336/2839instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:53:01.612CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Probiotic Lactobacillus strains protect against myelosuppression and immunosuppression in cyclophosphamide-treated mice
title Probiotic Lactobacillus strains protect against myelosuppression and immunosuppression in cyclophosphamide-treated mice
spellingShingle Probiotic Lactobacillus strains protect against myelosuppression and immunosuppression in cyclophosphamide-treated mice
Salva, Maria Susana
CYCLOPHOSPHAMIDE
IMMUNOBIOTICS
IMMUNOSUPPRESSION
LACTOBACILLUS CASEI CRL431
LACTOBACILLUS RHAMNOSUS CRL1506
MYELOPOIESIS
title_short Probiotic Lactobacillus strains protect against myelosuppression and immunosuppression in cyclophosphamide-treated mice
title_full Probiotic Lactobacillus strains protect against myelosuppression and immunosuppression in cyclophosphamide-treated mice
title_fullStr Probiotic Lactobacillus strains protect against myelosuppression and immunosuppression in cyclophosphamide-treated mice
title_full_unstemmed Probiotic Lactobacillus strains protect against myelosuppression and immunosuppression in cyclophosphamide-treated mice
title_sort Probiotic Lactobacillus strains protect against myelosuppression and immunosuppression in cyclophosphamide-treated mice
dc.creator.none.fl_str_mv Salva, Maria Susana
Marranzino, Gabriela
Villena, Julio Cesar
Agüero, Graciela
Alvarez, Gladis Susana
author Salva, Maria Susana
author_facet Salva, Maria Susana
Marranzino, Gabriela
Villena, Julio Cesar
Agüero, Graciela
Alvarez, Gladis Susana
author_role author
author2 Marranzino, Gabriela
Villena, Julio Cesar
Agüero, Graciela
Alvarez, Gladis Susana
author2_role author
author
author
author
dc.subject.none.fl_str_mv CYCLOPHOSPHAMIDE
IMMUNOBIOTICS
IMMUNOSUPPRESSION
LACTOBACILLUS CASEI CRL431
LACTOBACILLUS RHAMNOSUS CRL1506
MYELOPOIESIS
topic CYCLOPHOSPHAMIDE
IMMUNOBIOTICS
IMMUNOSUPPRESSION
LACTOBACILLUS CASEI CRL431
LACTOBACILLUS RHAMNOSUS CRL1506
MYELOPOIESIS
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv This work evaluated the capacity of two probiotic strains, Lactobacillus casei CRL431 and Lactobacillus rhamnosus CRL1506, to protect against myelosuppression and immunosuppression in cyclophosphamide (Cy)-treated mice. Changes inmature granulocytes and progenitor cells in bonemarrow (BM) and blood were studied. In addition, the ability of probiotics to accelerate the recovery of the immune response against the opportunistic pathogen Candida albicans was evaluated.We demonstrated for the first time that the preventive treatmentwith immunomodulatory lactobacilli such as L. casei CRL431 or L. rhamnosus CRL1506 was able to increase immature myeloid progenitors in the BM, allowing an early recovery of myeloid cells after Cy administration. Probiotic lactobacilli were also capable to induce an early recovery of neutrophils in blood, improve phagocytic cells recruitment to infectious sites and increase the resistance against the opportunistic pathogen C. albicans. Although deeper studies regarding the cellular and molecularmechanisms of probiotic actions are needed, these findings support the idea that strains like CRL431 and CRL1506 may accelerate the recovery of Cy-caused immunosuppression by immunopotentiating myeloid cells. Then, probiotic lactobacilli have the potential to be used as alternatives for lessening chemotherapy-induced immunosuppression in cancer patients.
Fil: Salva, Maria Susana. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Tucumán. Centro de Referencia para Lactobacilos (i); Argentina
Fil: Marranzino, Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Tucumán. Centro de Referencia para Lactobacilos (i); Argentina
Fil: Villena, Julio Cesar. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Tucumán. Centro de Referencia para Lactobacilos (i); Argentina
Fil: Agüero, Graciela. Universidad Nacional de Tucuman. Facultad de Bioquimica, Quimica y Farmacia. Instituto de Bioquimica Clinica Aplicada. Catedra de Bioquimica Clinica I; Argentina
Fil: Alvarez, Gladis Susana. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Tucumán. Centro de Referencia para Lactobacilos (i); Argentina. Universidad Nacional de Tucuman. Facultad de Bioquimica, Quimica y Farmacia. Instituto de Bioquimica Clinica Aplicada. Catedra de Bioquimica Clinica I; Argentina
description This work evaluated the capacity of two probiotic strains, Lactobacillus casei CRL431 and Lactobacillus rhamnosus CRL1506, to protect against myelosuppression and immunosuppression in cyclophosphamide (Cy)-treated mice. Changes inmature granulocytes and progenitor cells in bonemarrow (BM) and blood were studied. In addition, the ability of probiotics to accelerate the recovery of the immune response against the opportunistic pathogen Candida albicans was evaluated.We demonstrated for the first time that the preventive treatmentwith immunomodulatory lactobacilli such as L. casei CRL431 or L. rhamnosus CRL1506 was able to increase immature myeloid progenitors in the BM, allowing an early recovery of myeloid cells after Cy administration. Probiotic lactobacilli were also capable to induce an early recovery of neutrophils in blood, improve phagocytic cells recruitment to infectious sites and increase the resistance against the opportunistic pathogen C. albicans. Although deeper studies regarding the cellular and molecularmechanisms of probiotic actions are needed, these findings support the idea that strains like CRL431 and CRL1506 may accelerate the recovery of Cy-caused immunosuppression by immunopotentiating myeloid cells. Then, probiotic lactobacilli have the potential to be used as alternatives for lessening chemotherapy-induced immunosuppression in cancer patients.
publishDate 2014
dc.date.none.fl_str_mv 2014-09
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/2839
Salva, Maria Susana; Marranzino, Gabriela; Villena, Julio Cesar; Agüero, Graciela; Alvarez, Gladis Susana; Probiotic Lactobacillus strains protect against myelosuppression and immunosuppression in cyclophosphamide-treated mice; Elsevier Science; International Immunopharmacology; 22; 1; 9-2014; 209-221
1567-5769
url http://hdl.handle.net/11336/2839
identifier_str_mv Salva, Maria Susana; Marranzino, Gabriela; Villena, Julio Cesar; Agüero, Graciela; Alvarez, Gladis Susana; Probiotic Lactobacillus strains protect against myelosuppression and immunosuppression in cyclophosphamide-treated mice; Elsevier Science; International Immunopharmacology; 22; 1; 9-2014; 209-221
1567-5769
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://sciencedirect.com/science/journal/15675769
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.intimp.2014.06.017
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier Science
publisher.none.fl_str_mv Elsevier Science
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846782224500785152
score 12.982451

Publicaciones similares